The disappointing efficacy of the vaccine, dubbed “CVnCoV,” emerged after an interim analysis based on 134 Covid-19 cases in a study of nearly 40,000 volunteers in Europe and Latin America.
However, the results of CureVac, which is seen as an alternative to the AstraZeneca/Oxford and Johnson & Johnson vaccines that can cause fatal blood clots, although extremely rare, have lost hope in this regard. At the same time, the vaccine was expected to help low- and middle-income countries with global immunization goals.
THERE IS A 425 MILLION DOSE AGREEMENT WITH THE EU
On the other hand, the EU, which made a major supply agreement with CureVac, signed the company for 405 million doses of vaccine in November, 180 million of which are optional. This was followed by a memorandum of understanding with Germany for another 20 million doses.
SHARES DOWN OVER 50 PERCENT
CureVac’s shares traded in the US fell 50.6 percent to 46.81 in after-hours trading following the release of the data.
CureVac announced that at least 13 variants are responsible for Covid-19 infections that occurred during clinical trials. The company added that interim results show that the vaccine is effective in younger participants, but that it has not proven its effectiveness in those over 60, the age group most at risk for severe Covid.
“While we hope for a stronger interim result, we recognize that it will be difficult to demonstrate high efficacy in this unprecedented wide variety. We plan to continue towards final analysis with at least 80 additional cases, after which overall vaccine efficacy may change.”
COMMUNICABLE DISEASES SPECIALIST FROM JOHN HOPKINS UNIVERSITY: EVEN 47 PERCENT ACTIVITY IS VERY VALUABLE RIGHT NOW
However, infectious disease specialist at the Johns Hopkins Center for Health Security, Dr. Amesh Adalja said that he did not fully explain the effect of variants on the efficacy rate and still wants to see specific data on CureVac’s ability to stop serious illness, hospitalizations and death. “Even with a 47 percent efficacy in symptomatic disease, it is very valuable in the current situation we are in. “That’s all we wanted vaccines to do,” he said.
Virologist and dean of the National School of Tropical Medicine, Dr. Peter Hotez explained that it is not clear whether the problem is specific to the variants or the vaccine’s failure to produce high-neutralizing antibodies.
VACCINE TAILS CONTINUED IN THE NIGHT